Medicare holds firm on Alzheimer’s drug coverage policy
Despite pressure from Congress and advocates, CMS isn’t changing its coverage plan for new Alzheimer’s drugs anytime soon.
WASHINGTON — Despite pressure from Congress and advocates, Medicare isn’t changing its coverage plan for new Alzheimer’s drugs anytime soon.
Medicare on Thursday issued a statement reiterating its intent to require patient registries to collect data about how medications perform even after they gain full Food and Drug Administration approval. Eisai’s Leqembi could gain full approval within the next month, so time is running short for the agency to solidify details.
What's Your Reaction?
